---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-005246"
form_type: "8-K/A"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2024-01-19T23:59:59+00:00"
generated_at: "2026-06-06T21:05:20.130428+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools completes SomaLogic acquisition; provides audited FY2022 and unaudited 9M2023 financials

## Summary
- Acquisition closed Jan. 5, 2024; SomaLogic becomes wholly owned subsidiary of Standard BioTools.
- SomaLogic FY2022 revenue $97.7M, net loss $109.2M; FY2021 revenue $81.6M, net loss $87.5M.
- Pro forma unaudited combined financials filed for FY2022 and 9M2023 reflecting the acquisition.
- SomaLogic had $421.8M cash and equivalents and $647.4M total assets at Dec. 31, 2022.

## SEC filing metadata
- accession: 0001104659-24-005246
- form_type: 8-K/A
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2024-01-19T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000110465924005246/0001104659-24-005246-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000110465924005246/tm243472d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-005246
- JSON: https://secwatch.observer/filing/0001104659-24-005246.json
- Plain text: https://secwatch.observer/filing/0001104659-24-005246.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.